Compare Caesars Entertainment Inc (CZR) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Caesars Entertainment Inc vs Enveric Biosciences Inc — how do they compare? Caesars Entertainment Inc trades at $29.52 (market cap $6.02B), while Enveric Biosciences Inc trades at $1.48 (market cap $6.80M). The key difference: Caesars Entertainment Inc is far larger — about 885.3× Enveric Biosciences Inc's market cap, and Caesars Entertainment Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Caesars Entertainment Inc for 31 Days and Enveric Biosciences Inc for 14 Days on average.
| CZR | ENVB | |
|---|---|---|
Market Cap | $6.02B | $6.80M |
Volume | 6,412,151 | 64,867 |
Sector | Consumer Cyclical | Health |
52-Week High | $30.41 | $10.80 |
52-Week Low | $18.14 | $1.27 |
Typical Hold Time | 31 Days | 14 Days |
Enterprise Value | $29.91B | -$1.49M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Caesars Entertainment (CZR) trades at $29.54, showing minimal daily movement with a 0.15% gain. The stock faces bearish technical signals and has missed earnings expectations for three consecutive quarters, with negative profitability metrics including -3.99% net income margin. The pending $31 per share acquisition by Fertitta Entertainment provides a potential floor, while recent news highlights shareholder investigations into the deal's fairness. Cash flow trends show improvement with net cash flow narrowing from -$689M in 2022 to -$32M in 2025.
CZR presents a mixed outlook with acquisition upside limited to 5% from current levels, offset by fundamental challenges including consistent earnings misses and negative margins. Key risks include merger uncertainty and high debt load, while analyst sentiment remains cautious with 68% hold ratings. The stock offers speculative appeal for merger arbitrage but lacks organic growth catalysts.
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
